Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
beroterkib anhydrous (ASTX029)
i
Other names:
ASTX029, ASTX 029, ASTX-029
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Otsuka
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Related drugs:
‹
BVD-523 (17)
BAY86-9766 (16)
ERAS-007 (13)
VTX-11e (5)
JSI-1187 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
BVD-523 (17)
BAY86-9766 (16)
ERAS-007 (13)
VTX-11e (5)
JSI-1187 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
›
Associations
(4)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia (NCT06113289)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Suspended
Phase 1/2
M.D. Anderson Cancer Center
Suspended
Last update posted :
02/12/2025
Initiation :
02/08/2024
Primary completion :
05/01/2027
Completion :
05/01/2029
KRAS • NF1 • PTPN11
|
Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login